Nisa Investment Advisors LLC Sells 4,325 Shares of Cencora, Inc. (NYSE:COR)

Nisa Investment Advisors LLC reduced its holdings in Cencora, Inc. (NYSE:COR) by 5.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 70,765 shares of the company’s stock after selling 4,325 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Cencora were worth $15,899,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in COR. Lake Street Advisors Group LLC increased its position in Cencora by 1.3% in the 3rd quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock worth $769,000 after buying an additional 43 shares during the period. Venturi Wealth Management LLC increased its position in Cencora by 1.0% during the third quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock worth $1,001,000 after acquiring an additional 46 shares during the period. Prime Capital Investment Advisors LLC boosted its holdings in Cencora by 1.2% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock valued at $848,000 after purchasing an additional 46 shares during the period. J.W. Cole Advisors Inc. increased its holdings in shares of Cencora by 1.3% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company’s stock worth $826,000 after purchasing an additional 48 shares during the period. Finally, Impact Partnership Wealth LLC raised its position in shares of Cencora by 2.6% during the third quarter. Impact Partnership Wealth LLC now owns 2,042 shares of the company’s stock valued at $460,000 after buying an additional 51 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Up 0.8 %

Shares of COR stock opened at $247.12 on Thursday. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company has a market capitalization of $47.76 billion, a P/E ratio of 32.91, a P/E/G ratio of 1.51 and a beta of 0.49. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $253.27. The firm has a 50-day moving average price of $237.26 and a 200 day moving average price of $234.40.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were issued a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s payout ratio is presently 29.29%.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock worth $17,790,912 in the last three months. Insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

COR has been the topic of several research reports. Evercore ISI boosted their price target on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Leerink Partners cut their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. UBS Group increased their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Robert W. Baird lifted their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $275.60.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.